Chrischilles Elizabeth A, Schneider Kathleen M, Schroeder Mary C, Letuchy Elena, Wallace Robert B, Robinson Jennifer G, Brooks John M
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa.
Schneider Research Associates, LLC, Des Moines, Iowa.
J Am Geriatr Soc. 2016 Mar;64(3):526-35. doi: 10.1111/jgs.13953. Epub 2016 Mar 1.
To determine whether function-related indicators (FRIs), derived from preadmission claims data, help explain the frequent practice of forgoing secondary prevention medications observed in Medicare.
Retrospective cohort.
National Medicare data.
Elderly Medicare beneficiaries discharged alive from an acute myocardial infarction (AMI) hospitalization in 2007-2008 (N = 184,156).
Study outcomes were number of guideline-recommended secondary prevention medications (statins, beta-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) used after discharge and 12-month survival. Preadmission data (FRIs, cardiovascular conditions, comorbid conditions), type of AMI (non-ST-elevation myocardial infarction, anterior, other), and procedures and complications during the hospitalization were from claims data.
Function-related indicators (FRIs) were common before admission; 50% of individuals had at least one (range 0-11). After discharge, 85.8% used at least one class of guideline medication, and 30.2% used all three; 19.6% died within 12 months. Each additional FRI reduced the likelihood of receiving all three medication classes by 5% (adjusted odds ratio = 0.95, 95% confidence interval (CI) = 0.94-0.96) and increased 12-month mortality by 20% (adjusted hazard ratio (aHR) = 1.20, 95% CI = 1.19-1.21). Individuals taking all three classes of medication were 30% less likely to die within 12 months than those not taking guideline medications (aHR = 0.70, 95% CI = 0.67-0.73). Similar survival benefit was observed in individuals with and without functional impairments.
Greater impairment in preadmission functional status, using a measure derived from claims data, was associated with less use of secondary prevention medications after AMI. Survival benefits of taking these medications were consistent across functional impairment levels.
确定从入院前索赔数据得出的功能相关指标(FRIs)是否有助于解释医疗保险中常见的放弃二级预防药物的做法。
回顾性队列研究。
国家医疗保险数据。
2007 - 2008年因急性心肌梗死(AMI)住院后存活出院的老年医疗保险受益人(N = 184,156)。
研究结局为出院后使用的指南推荐的二级预防药物(他汀类药物、β受体阻滞剂以及血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂)数量和12个月生存率。入院前数据(功能相关指标、心血管疾病、合并症)、AMI类型(非ST段抬高型心肌梗死、前壁、其他)以及住院期间的手术和并发症来自索赔数据。
入院前功能相关指标很常见;50%的个体至少有一项(范围为0 - 11项)。出院后,85.8%的人使用了至少一类指南用药,30.2%的人使用了全部三类;19.6%的人在12个月内死亡。每增加一项功能相关指标,接受全部三类药物治疗的可能性降低5%(调整后的优势比 = 0.95,95%置信区间(CI)= 0.94 - 0.96),12个月死亡率增加20%(调整后的风险比(aHR)= 1.20,95% CI = 1.19 - 1.21)。服用全部三类药物的个体在12个月内死亡的可能性比未服用指南用药的个体低30%(aHR = 0.70,95% CI = 0.67 - 0.73)。在有和没有功能障碍的个体中均观察到类似的生存获益。
使用从索赔数据得出的指标衡量,入院前功能状态损害越大,AMI后二级预防药物的使用越少。服用这些药物的生存获益在不同功能障碍水平上是一致的。